Cannabinoid CB1 receptor mediates glucocorticoid effects on hormone secretion induced by volume and osmotic changes


Autoria(s): Ruginsk, S. G.; Uchoa, E. T.; Elias, L. L. K.; Antunes-Rodrigues, J.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/10/2013

24/10/2013

2012

Resumo

1. The present study provides the first in vivo evidence that the cannabinoid CB1 receptor mediates the effects of dexamethasone on hormone release induced by changes in circulating volume and osmolality. Male adult rats were administered with the CB1 receptor antagonist rimonabant (10 mg/Kg, p.o.), followed or not in 1 hour by dexamethasone (1 mg/Kg, i.p.). Extracellular volume expansion (EVE, 2 mL/100 g of body weight, i.v.) was performed 2 hours after dexamethasone or vehicle treatment using either isotonic (I-EVE, 0.15 mol/L) or hypertonic (H-EVE, 0.30 mol/L) NaCl solution. Five minutes after EVE, animals were decapitated and trunk blood was collected for all plasma measurements. 2. Rimonabant potentiated oxytocin (OT) secretion induced by H-EVE and completely reversed the inhibitory effects of dexamethasone in response to the same stimulus. These data suggest that glucocorticoid modulation of OT release is mediated by the CB1 receptor. 3. Although dexamethasone did not affect vasopressin (AVP) secretion induced by H-EVE, the administration of rimonabant potentiated AVP release in response to the same stimulus, supporting the hypothesis that the CB1 receptor regulates AVP secretion independently of glucocorticoid-mediated signalling. 4. Dexamethasone alone did not affect atrial natriuretic peptide (ANP) release stimulated by I-EVE or H-EVE. However, pretreatment with rimonabant potentiated ANP secretion induced by H-EVE, suggesting a possible role for the CB1 receptor in the control of peripheral factors that modulate cardiovascular function. 5. Rimonabant also reversed the inhibitory effects of dexamethasone on H-EVE-induced corticosterone secretion, reinforcing the hypothesis that the CB1 receptor may be involved in the negative feedback exerted by glucocorticoids on the activity of the hypothalamicpituitaryadrenal axis. 6. Collectively, the results of the present study indicate that the CB1 receptor modulates neurohypophyseal hormone secretion and systemic factors, such as corticosterone and ANP, thus participating in homeostatic responses to altered extracellular volume and plasma tonicity.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Brazil)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-Brazil [2008/50611-8]

Identificador

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, MALDEN, v. 39, n. 2, supl. 1, Part 3, pp. 151-154, FEB, 2012

0305-1870

http://www.producao.usp.br/handle/BDPI/35880

10.1111/j.1440-1681.2011.05658.x

http://dx.doi.org/10.1111/j.1440-1681.2011.05658.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

MALDEN

Relação

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Direitos

closedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #ATRIAL NATRIURETIC PEPTIDE #CB1 RECEPTOR #CORTICOSTERONE #DEXAMETHASONE #OXYTOCIN #VASOPRESSIN #ATRIAL-NATRIURETIC-PEPTIDE #RAT #EXPANSION #TRANSMISSION #VASOPRESSIN #INHIBITION #ANTAGONIST #MODULATION #OXYTOCIN #PATHWAYS #PHARMACOLOGY & PHARMACY #PHYSIOLOGY
Tipo

article

original article

publishedVersion